TerminatedPhase 2NCT04764448

A Study of Belcesiran in Patients With AATLD

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Principal Investigator: Thomas Bowman, MD
Dicerna Pharmaceuticals / Novo Nordisk
Intervention: Belcesiran(drug)
Enrollment: 16 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2021 – 2024

Study locations (23)

University of California - San Diego, La Jolla, California, United States
University of Florida, Gainesville, Florida, United States
Medical University of South Carolina, Charleston, South Carolina, United States
St Vincent's Hospital Melbourne, Melbourne, Australia
Medizinische Universitaet Innsbruck, Innsbruck, Austria
Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, Canada
CHU Bordeaux - Hopital Haut-Leveque - Centre François Magendie, Pessac, France
Universitaetsklinikum Aachen, AoeR, Aachen, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany
Beaumont Hospital, Dublin, Ireland
Leiden University Medical Center, Leiden, Netherlands
Auckland Clinical Studies, Grafton, Auckland, New Zealand
Waikato Hospital, Hamilton, New Zealand
Hospital da Senhora da Oliveira - Guimaraes, Creixomil, Portugal
+8 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04764448 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency →

← Back to all trials